{"entity":{"id":"phanes-therapeutics","kind":"company","name":"Phanes Therapeutics","aka":["Phanes Therapeutics, Inc."],"tldr":"Phanes Therapeutics is a San Diego biotech whose bispecific antibodies pair a tumour antigen with an immune signal; peluntamig hits DLL3 and CD47 in small cell lung cancer and spevatamig hits Claudin 18.2 and CD47 in stomach and pancreatic cancer.","summary":"Phanes Therapeutics develops bispecific antibodies using its PACbody, SPECpair and ATACCbody platforms. Peluntamig (PT217) binds DLL3 and CD47 and has orphan and fast track designations in small cell lung cancer and neuroendocrine carcinomas; spevatamig (PT886) binds Claudin 18.2 and CD47 for gastric and pancreatic cancers; mavrostobart (PT199) is a CD73 antibody being tested with PD-1 blockade and chemotherapy. All three are in phase 1/2 trials.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.phanestherapeutics.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["peluntamig","spevatamig","mavrostobart"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"San Diego, California","country":"US","companyType":"biotech","website":"https://www.phanestherapeutics.com/","investors":[],"funding":[]},"route":"/companies/phanes-therapeutics/","neighbours":{"drug":[{"id":"mavrostobart","kind":"drug","name":"Mavrostobart","route":"/drugs/mavrostobart/"},{"id":"peluntamig","kind":"drug","name":"Peluntamig","route":"/drugs/peluntamig/"},{"id":"spevatamig","kind":"drug","name":"Spevatamig","route":"/drugs/spevatamig/"}]}}